About Immedica
Immedica is a Healthcare company based in Stockholm (Sweden) founded in 2017, and was acquired by KKR in April 2024. Therapeutic agents for oncology, neurology, and related diseases are developed. Immedica has completed 2 acquisitions, including Marinus Pharma and Neurocrine. Its chief executive, as recorded, is Anders Edvell. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Beactica, Asgard Therapeutics and Alligator Bioscience; 2 of its 3 listed competitors have raised funding.
Company details
Immedica was founded in 2017 in Stockholm, Sweden, as a developer of therapeutic agents targeting oncology, neurology, infectious diseases, ophthalmology, and inflammatory conditions. Drugs such as Arlevert and Vertisan have been created for vertigo treatment across various origins, while additional agents address corneal neovascularization. Operations focus on pharmaceutical innovation within these medical sectors.
- Headquarters Stockholm, Sweden
- Stage Acquired
- SectorsHealthcare
- Website immedica.com/en
- Social LinkedIn
- Acquired by KKR (Apr 2024)
- InvestorsKKR
& 1 more
- Investments & AcquisitionsMarinus Pharma
& 1 more
- Acquired byKKR
(Apr 2024)
Investors in Immedica
Immedica has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include KKR and Impilo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Impilo is focused on healthcare investments in Nordic regions. | impilo.se | Stockholm, Sweden |
Investor details for Immedica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immedica
38 people are tracked at Immedica (25 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
Anders Edvell | CEO | Leadership |
Lena Jacobson | Head Of Market Access & Health Economics | Leadership |
Joerg van Den Boom | Medical Director DACH | Leadership |
Joseph Auci | Vice President Of Market Access | Leadership |
Ingrid From | Director Regulatory Affairs At Immedica Pharma | Leadership |
Armelle Richiardi | General Manager France & Benelux | Leadership |
Anna Sestan | Head Of Accounting And Reporting | Leadership |
Carl Belmadani | Chief Commercial Officer | Leadership |
Gunilla Mickelsson | Head Of Europe | Leadership |
Håkan Garpenstrand | Head Of Business Development | Leadership |
Simon Falk | Chief Financial Officer | Leadership |
Louise Mehkri | Head Of Product Strategy & International Business | Leadership |
Linda Holmström | Head Of Communication | Leadership |
Alfred Haggren | Director, Business Development | Leadership |
Martin Brink | Head Of Manufacturing And Technology Transfer | Leadership |
Fabrizio Zucca | General Manager DACH | Leadership |
Michael Romano | National Sales Director | Leadership |
Ashraf Attia | Regional Director, Head Of Mena& Turkey | Leadership |
Fred Bero | Vice President, Sales & Marketing | Leadership |
Paula Rentero | General Manager Iberia Immedica Pharma | Leadership |
18 more people are available in the full profile.
Complete people profiles for Immedica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immedica
Immedica has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Marinus Pharma and Neurocrine.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of small molecule therapeutics for endocrine and CNS disorders | neurocrine.com | San Diego, United States | 1992 | Jan 2026 | •••• | |
Developer of therapeutics to treat seizure disorders | marinuspharma.com | Radnor, United States | 2003 | Dec 2024 | $151M |
Complete acquisition details for Immedica
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immedica
4 dated milestones of Immedica across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Immedica is founded.
- Exit Acquired by KKR.
- Acquisition Acquires Marinus Pharma.
- Acquisition Acquires Neurocrine.
Competitors of Immedica
Immedica has 3 listed competitors in our database, 2 of them funded. They include Beactica, Asgard Therapeutics and Alligator Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beactica.com | 2006 | Uppsala, Sweden | Develops small molecule drugs for oncology | |||
| asgardthx.com | 2017 | Lund, Sweden | $39.75M | 7 | Cancer immunotherapies are developed via direct cell reprogramming techniques. | |
| alligatorbioscience.se | 2001 | Lund, Sweden | $10M | Alligator Bioscience is focused on tumor-directed cancer immunotherapy development. |
Detailed competitors of Immedica
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immedica
The website of Immedica (immedica.com) receives about 3.9K visits a month.
- Monthly visits3.9K
▼ 1.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immedica
Complete news archive for Immedica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immedica
Immedica was founded in 2017.
Immedica is headquartered in Stockholm, Sweden.
Anders Edvell is the CEO of Immedica, as recorded in our data.
Immedica was founded in 2017 in Stockholm, Sweden, as a developer of therapeutic agents targeting oncology, neurology, infectious diseases, ophthalmology, and inflammatory conditions. Drugs such as Arlevert and Vertisan have been created for vertigo treatment across various origins, while additional agents address corneal neovascularization. Operations focus on pharmaceutical innovation within these medical sectors.
Immedica's top competitors include Alligator Bioscience, Beactica and Asgard Therapeutics.
Immedica has made 2 acquisitions, including Marinus Pharma, and Neurocrine.
Yes. Immedica was acquired by KKR in April 2024.